LYTIR

Insider · SEC Form 4 · 10% Owner

TCG Crossover GP II, LLC

In the 12 months to Nov 19, 2026, on the open market: sold $6.9M of SRZN. Filed 2 business days after the trade.

Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these

  1. SRZNSold: Surrozen, Inc./DE Jul 22, 2026 325,000 shares filed Jul 24, 2026 2 transactions filing $6.9M

Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.

Stakes filed (13D/13G)

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Filings made under this filer's SEC CIK in the same 12 months, newest first; the figure is the percentage the filing states. Every recent 13D and 13G

  1. ALTTCG Crossover GP II, LLC filed Nov 16, 2026 Schedule 13G/A passive issuer: Altimmune, Inc. filing 4.9%
  2. TNGXTCG Crossover GP II, LLC filed Nov 16, 2026 Schedule 13G/A passive issuer: Tango Therapeutics, Inc. filing 4.6%
  3. GLUETCG Crossover GP II, LLC filed Nov 16, 2026 Schedule 13G/A passive issuer: Monte Rosa Therapeutics, Inc. filing 4.4%
  4. LBRXTCG Crossover GP II, LLC filed Nov 16, 2026 Schedule 13G/A passive issuer: LB Pharmaceuticals Inc. filing 2.4%
  5. SRZNTCG Crossover GP II, LLC filed Nov 16, 2026 Schedule 13G/A passive issuer: Surrozen, Inc. filing 0%
  6. TRAXTCG Crossover GP II, LLC filed Aug 14, 2026 Schedule 13G passive issuer: First Tracks Biotherapeutics, Inc. filing 8.3%
  7. TNGXTCG Crossover GP II, LLC filed Aug 14, 2026 Schedule 13G/A passive issuer: Tango Therapeutics, Inc. filing 7%
  8. LBRXTCG Crossover GP II, LLC filed Aug 14, 2026 Schedule 13G/A passive issuer: LB Pharmaceuticals Inc. filing 5%
  9. ALXOTCG Crossover GP II, LLC filed Aug 14, 2026 Schedule 13G/A passive issuer: ALX Oncology Holdings Inc. filing 4.2%
  10. FULCTCG Crossover GP II, LLC filed Aug 14, 2026 Schedule 13G/A passive issuer: Fulcrum Therapeutics, Inc. filing 0%
  11. SRZNTCG Crossover GP II, LLC filed Jul 24, 2026 Schedule 13G/A passive issuer: Surrozen, Inc./DE filing 4.9%
  12. ZLABTCG Crossover GP II, LLC filed Jun 11, 2026 Schedule 13G passive issuer: Zai Lab Ltd filing 2.6%